The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
Title:
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
Author:
Nasonov, E. L. Mazurov, V. I. Lila, A. M. Dubinina, T. V. Gaidukova, I. Z. Lapshina, S. A. Klimenko, A. A. Somov, D. V. Lukyanov, S. A. Chudakov, D. M. Zvyagin, I. V. Britanova, O. V. Korolev, M. A. Abdulganieva, D. I. Krechikova, D. G. Kastanayan, A. A. Eliseeva, L. V. Samigullina, R. R. Povarova, T. V. Antipova, O. V. Smakotina, S. A. Soboleva, V. N. Nesmeyanova, O. B. Plaksina, T. V. Soroka, N. F. Vinogradova, I. B. Rebrov, A. P. Kropotina, T. V. Maslyansky, A. L. Zinkina-Orikhan, A. V. Linkova, Yu. N. Pukhtinskaya, P. S. Morozova, M. A. Vinderskaya, G. A.